Supernus Pharmaceuticals, Inc. (SUPN) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $50.11. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of SUPN = $143.04 (+185.5% from the current price, the stock appears undervalued). Analyst consensus target is SUPN = $62 (+23.1% upside).
Valuation: SUPN trades at a trailing Price-to-Earnings (P/E) of -75.8 (S&P 500 average ~25).
Financials: revenue is $719M, +2.9%/yr average growth. Net income is $39M (loss), growing at +1754.3%/yr. Net profit margin is -5.4% (negative). Gross margin is 89.6% (+2.7 pp trend).
Balance sheet: total debt is $41M against $1.1B equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 1.9 (strong liquidity). Debt-to-assets is 2.8%. Total assets: $1.5B.
Analyst outlook: 9 / 14 analysts rate SUPN as buy (64%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 86/100 (Pass), Growth 73/100 (Pass), Past 75/100 (Partial), Health 100/100 (Pass), Moat 70/100 (Pass), Future 67/100 (Pass), Income 10/100 (Fail).
